How should we incorporate molecular data in treatment decisions for ALL?
It is time to pay more attention to genetic heterogeneity of adult ALL before we decide therapy.
Targeted therapies are rapidly emerging, and replacing chemo in ALL.
Our review at Blood Cancer Discovery is out today! Link👇
